Trial · NCT03389620
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Numerical Rating Scale (Averaged Over Past 24 Hours) | Baseline to 2 months | The pain numerical rating scale (NRS) is a well-validated tool for quantitatively assessing patients' pain. The NRS asks patients to rate their current pain intensity on an 11-point scale ranging from 0 ("no pain") to 10 ("worst possible pain") |
| Secondary | Change in Pain Numerical Rating Scale (Averaged Over Past 24 Hours) | Baseline, 2 weeks, 4 months | The pain numerical rating scale (NRS) is a well-validated tool for quantitatively assessing patients' pain. The NRS asks patients to rate their current pain intensity on an 11-point scale ranging from 0 ("no pain") to 10 ("worst possible pain") |
| Secondary | Change in Neck Disability Index (NDI) | Baseline, 2 weeks, 2 months, 4 months | The NDI a well-validated measurement tool that contains 10 items: seven related to activities of daily living, two related to pain, and one related to concentration. Each item is scored from 0 to 5 and the total score is expressed as a percentage, with higher scores corresponding to greater disability. |
| Secondary | Change in EuroQol-5 Dimension (EQ-5D) Visual Analog Scale (VAS) | Baseline, 2 weeks, 2 months, 4 months | EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. It is a well-validated tool for health status measurement, and for health quality-of-life in cervicogenic radicular pain. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labeled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). |
| Secondary | Change in EuroQol-5 Dimension (EQ-5D) Index Score | Baseline, 2 weeks, 2 months, 4 months | EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. It is a well-validated tool for health status measurement, and for health quality-of-life in cervicogenic radicular pain. The index score was derived using the time trade-off (TTO) valuation method and ranges from approximately 0 (dead) to 1 (full health), with negative values indicating health states worse than death. |
| Secondary | Change in Work Ability Index (WAI) Absenteeism | Baseline, 2 weeks, 2 months, 4 months | The Work Ability Index (WAI) is a validated, reliable measure of a worker's ability to do his or her job that has been shown to predict work disability, retirement and mortality. The WAI is scored on a scale of 7 to 49, where higher scores indicate better work ability. |
| Secondary | Change in Work Ability Index (WAI) Presenteeism | Baseline, 2 weeks, 2 months, 4 months | The Work Ability Index (WAI) is a validated, reliable measure of a worker's ability to do his or her job that has been shown to predict work disability, retirement and mortality. The WAI is scored on a scale of 7 to 49, where higher scores indicate better work ability. |
| Secondary | Change in Work Ability Index (WAI) Work Productivity Loss | Baseline, 2 weeks, 2 months, 4 months | The Work Ability Index (WAI) is a validated, reliable measure of a worker's ability to do his or her job that has been shown to predict work disability, retirement and mortality. The WAI is scored on a scale of 7 to 49, where higher scores indicate better work ability. |
| Secondary | Change in Work Ability Index (WAI) Activity Impairment | Baseline, 2 weeks, 2 months, 4 months | The Work Ability Index (WAI) is a validated, reliable measure of a worker's ability to do his or her job that has been shown to predict work disability, retirement and mortality. The WAI is scored on a scale of 7 to 49, where higher scores indicate better work ability. |
| Secondary | Number of Participants With Minor Adverse Events | Immediately post-procedure, 2 days post procedure | |
| Secondary | Number of Participants With Major Adverse Events | Immediately post-procedure, 2 days post procedure | |
| Other | Number of Participants With Inadvertent Intravascular Contrast Injections | During procedure | |
| Other | Number of Participants With Contrast Spread Into the Medial Half of the Neuroforamen | During procedure |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03389620/registered